Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VENKAT PAVAN R KANCHARLA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205091758
CMS profile
99298
Location
PALM BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$9,492.12

270 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $9,098.59 266
Travel and Lodging $337.87 1
Education $55.66 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $1,004.07 18
Roche Products Limited $709.58 2
Merck Sharp & Dohme LLC $591.70 16
Seagen Inc. $560.33 18
Amgen Inc. $503.13 14
Incyte Corporation $456.06 8
PFIZER INC. $386.00 16
Janssen Biotech, Inc. $364.51 13
NOVARTIS PHARMACEUTICALS CORPORATION $343.44 20
GENZYME CORPORATION $326.97 9
Mirati Therapeutics, Inc. $299.10 5
BeiGene USA, Inc. $261.54 6
Celgene Corporation $215.93 14
Eisai Inc. $213.80 6
ABBVIE INC. $200.02 4
E.R. Squibb & Sons, L.L.C. $199.11 5
Astellas Pharma US Inc $198.42 5
Genentech USA, Inc. $190.81 4
Gilead Sciences, Inc. $169.73 3
Regeneron Healthcare Solutions, Inc. $167.97 3
Daiichi Sankyo Inc. $160.82 8
G1 Therapeutics, Inc. $158.81 6
Novocure Inc. $158.22 1
Kite Pharma, Inc. $155.45 2
Pharmacyclics LLC, An AbbVie Company $135.79 5
Ipsen Biopharmaceuticals, Inc $127.30 1
Bayer Healthcare Pharmaceuticals Inc. $118.69 6
Takeda Pharmaceuticals U.S.A., Inc. $95.92 4
Genentech, Inc. $93.28 1
Lilly USA, LLC $78.35 5
Karyopharm Therapeutics Inc. $77.67 4
EMD Serono, Inc. $73.39 3
GlaxoSmithKline, LLC. $67.62 4
Pharmacosmos Therapeutics Inc. $66.02 3
TAIHO ONCOLOGY, INC. $54.04 3
Exelixis Inc. $45.40 2
ARRAY BIOPHARMA INC $42.14 2
Puma Biotechnology, Inc. $35.79 2
NESTLE HEALTHCARE NUTRITION INC. $34.58 2
Genmab U.S., Inc. $31.80 1
Rigel Pharmaceuticals, Inc. $28.25 2
Mylan Institutional Inc. $25.03 1
SERVIER PHARMACEUTICALS LLC $24.86 1
Apellis Pharmaceuticals, Inc. $24.83 1
Adaptive Biotechnologies Corporation $24.64 1
Blueprint Medicines Corporation $24.24 1
Stemline Therapeutics Inc. $22.24 1
Alexion Pharmaceuticals, Inc. $22.22 1
TerSera Therapeutics LLC $21.70 1
JAZZ PHARMACEUTICALS INC. $20.16 1
CTI BioPharma Corp. $18.16 1
Heron Therapeutics, Inc. $17.56 1
ADC Therapeutics America, Inc. $15.59 1
Agios Pharmaceuticals, Inc. $15.37 1
Verity Pharmaceuticals Inc. $13.97 1

Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VENKAT PAVAN R KANCHARLA

NPI 1205091758 · CMS profile ID 99298

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PALM BAY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205091758?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205091758?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205091758?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VENKAT PAVAN R KANCHARLA, NPI 1205091758, CMS profile ID 99298, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 270 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1205091758?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

270 matching records · $9,492.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 270 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 270.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $9.2110/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995688341 CMS
Mirati Therapeutics, Inc. $22.3910/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057994233 CMS
Karyopharm Therapeutics Inc. $27.4710/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056910323 CMS
Amgen Inc. $11.8910/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020693979 CMS
Celgene Corporation $18.0410/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015518929 CMS
Novartis Pharmaceuticals Corporation $19.1110/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337027 CMS
G1 Therapeutics, Inc. $20.3210/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059919307 CMS
Seagen Inc. $20.6109/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995688327 CMS
GlaxoSmithKline, LLC. $15.7109/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002317095 CMS
Pharmacosmos Therapeutics Inc. $16.4509/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046252829 CMS
AstraZeneca Pharmaceuticals LP $114.5009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014334957 CMS
Genmab U.S., Inc. $31.8009/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051349053 CMS
Novartis Pharmaceuticals Corporation $21.5309/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337031 CMS
Incyte Corporation $124.8009/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044509643 CMS
Amgen Inc. $9.8109/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020693981 CMS
Janssen Biotech, Inc. $42.1809/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988101781 CMS
AstraZeneca Pharmaceuticals LP $15.3409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011287639 CMS
GENZYME CORPORATION $27.0809/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050143117 CMS
Astellas Pharma US Inc $23.0809/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034495445 CMS
BeiGene USA, Inc. $104.1709/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189041 CMS
Incyte Corporation $16.9309/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044509547 CMS
Novartis Pharmaceuticals Corporation $21.7509/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337019 CMS
Pharmacyclics LLC, An AbbVie Company $30.3209/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288111 CMS
Seagen Inc. $2.8809/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995688313 CMS
Novartis Pharmaceuticals Corporation $17.0209/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337023 CMS
Eisai Inc. $15.9208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023336185 CMS
AstraZeneca Pharmaceuticals LP $18.1208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015099719 CMS
Kite Pharma, Inc. $124.4608/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270323 CMS
Exelixis Inc. $20.7908/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044593511 CMS
Gilead Sciences, Inc. $20.8308/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025786179 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.7608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055424143 CMS
AstraZeneca Pharmaceuticals LP $23.2808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016207889 CMS
Janssen Biotech, Inc. $124.4608/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988101745 CMS
PFIZER INC. $25.0008/24/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049174137 CMS
PFIZER INC. $14.7808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050692703 CMS
AstraZeneca Pharmaceuticals LP $20.5108/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014170885 CMS
ABBVIE INC. $28.7808/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997598083 CMS
Janssen Biotech, Inc. $23.3008/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988101763 CMS
Amgen Inc. $9.2908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020693977 CMS
Pharmacosmos Therapeutics Inc. $24.6908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046252819 CMS
Amgen Inc. $7.2808/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020693975 CMS
Karyopharm Therapeutics Inc. $15.6108/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056910319 CMS
Rigel Pharmaceuticals, Inc. $8.8108/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033436355 CMS
Celgene Corporation $22.2708/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015518893 CMS
Seagen Inc. $125.0008/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995688479 CMS
Astellas Pharma US Inc $17.6408/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034397837 CMS
Novartis Pharmaceuticals Corporation $7.1408/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337011 CMS
Novartis Pharmaceuticals Corporation $23.3908/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992337015 CMS
Lilly USA, LLC $16.2408/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032153603 CMS
Lilly USA, LLC $0.8208/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032646349 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,389.78 246
PY2020 $6,391.92 188
PY2021 $8,764.77 260
PY2022 $10,106.54 262
PY2023 $9,492.12 270
PY2024 $14,184.27 287
PY2025 $30,766.14 249

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $150.00 1
PY2025 Principal investigator $419,595.67 125
PY2024 Principal investigator $260,104.53 173
PY2023 Principal investigator $194,397.52 62
PY2022 Principal investigator $150,869.81 31
PY2021 Recipient $1,417.45 1
PY2021 Principal investigator $239,699.09 27
PY2020 Recipient $4,360.00 1
PY2020 Principal investigator $85,814.19 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,000.00 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547707
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706757
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706759
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706761
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706863
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706937
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706939
Principal investigator 1 PFIZER INC. $3,187.76 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228706941
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707876
Principal investigator 1 PFIZER INC. $27.54 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707878
Principal investigator 1 PFIZER INC. $26.00 12/08/2025 Non-covered Recipient Entity
Cancer Care Centers of Brevard Inc
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228707880
Principal investigator 1 BioNTech SE $245.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019328
Principal investigator 1 BioNTech SE $245.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019580
Principal investigator 1 Eli Lilly and Company $90.00 11/20/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187891602
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387493
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019570
Principal investigator 1 BioNTech SE $92.00 11/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019576
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388265
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365263
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365267
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228726426
Principal investigator 1 Daiichi Sankyo Inc. $4,774.00 10/14/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387491
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749102
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387487
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388261
Principal investigator 1 Daiichi Sankyo Inc. $588.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388263
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941475
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941498
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941579
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941591
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941607
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medical Oncology
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941697
Principal investigator 1 PFIZER INC. $1,641.00 08/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228720619
Principal investigator 1 PFIZER INC. $500.00 08/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744375
Principal investigator 1 PFIZER INC. $723.00 08/11/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228766741
Principal investigator 1 Daiichi Sankyo Inc. $6,058.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387489
Principal investigator 1 Genentech, Inc. $1,500.00 07/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676413
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard - Melbourne Pine
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941554
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743942
Principal investigator 1 PFIZER INC. $2,518.00 06/16/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228790391
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387485
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228723076
Principal investigator 1 Genentech, Inc. $4,089.00 05/19/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676346
Principal investigator 1 Genentech, Inc. $1,350.00 05/12/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681522
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,534.80 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547699
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,712.07 04/30/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547697
Principal investigator 1 Eli Lilly and Company $18,227.00 04/29/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187892426
Principal investigator 1 Genentech, Inc. $1,500.00 04/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676312
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365261
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365265
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medi
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941633
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne Pine-Medi
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941685
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745173
Principal investigator 1 PFIZER INC. $860.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745952
Principal investigator 1 PFIZER INC. $250.00 04/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746511
Principal investigator 1 Genentech, Inc. $2,168.00 04/08/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676333
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387473
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387475
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387477
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387479
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387481
Principal investigator 1 Daiichi Sankyo Inc. $590.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387483
Principal investigator 1 PFIZER INC. $9,011.00 03/24/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228795253
Principal investigator 1 Eli Lilly and Company $565.00 03/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187887098
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 03/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941563
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 03/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941647
Principal investigator 1 PFIZER INC. $750.00 03/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744710
Principal investigator 1 PFIZER INC. $3,231.00 03/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228749168
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388259
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,000.00 03/05/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547703
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387229
Recipient Eli Lilly and Company $150.00 02/15/2025 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 1187873605
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941484
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941509
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941528
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941541
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941657
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941675
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941707
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 02/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941718
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743947
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744132
Principal investigator 1 PFIZER INC. $281.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744312
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744316
Principal investigator 1 PFIZER INC. $750.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744383
Principal investigator 1 PFIZER INC. $2,147.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744659
Principal investigator 1 PFIZER INC. $2,200.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744830
Principal investigator 1 PFIZER INC. $50.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228745726
Principal investigator 1 PFIZER INC. $2,931.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747838
Principal investigator 1 PFIZER INC. $330.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747842
Principal investigator 1 PFIZER INC. $1,843.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747943
Principal investigator 1 PFIZER INC. $2,042.00 02/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228747947
Principal investigator 1 Daiichi Sankyo Inc. $6,451.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387197
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387199
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387201
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387203
Principal investigator 1 Daiichi Sankyo Inc. $590.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387205
Principal investigator 1 Daiichi Sankyo Inc. $90.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387207
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387209
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387211
Principal investigator 1 Daiichi Sankyo Inc. $236.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387213
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387215
Principal investigator 1 Eli Lilly and Company $0.04 02/06/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CARE CLINICAL TRIALS LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187886856
Principal investigator 1 Genentech, Inc. $1,350.00 02/05/2025 Non-covered Recipient Entity
US Oncology Research, LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211681550
Principal investigator 1 Genentech, Inc. $1,500.00 02/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211676261
Principal investigator 1 PFIZER INC. $13,605.00 02/03/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228791554
Principal investigator 1 Eli Lilly and Company $0.14 01/28/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187874607
Principal investigator 1 Eli Lilly and Company $65,656.00 01/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187893264
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,060.65 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185547701
Principal investigator 1 Amgen Inc. $1,483.36 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246639885
Principal investigator 1 AstraZeneca Pharmaceuticals LP $680.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185547695
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,040.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185547705
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U304 No dispute reported 06/30/2026 1223365269
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard Melbourne
DS1062-A-U303 No dispute reported 06/30/2026 1223365271
Principal investigator 1 Eli Lilly and Company $956.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187874609
Principal investigator 1 Eli Lilly and Company $105,839.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187875431
Principal investigator 1 Eli Lilly and Company $31,772.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC No dispute reported 06/30/2026 1187876523
Principal investigator 1 Eli Lilly and Company $1,549.95 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
Not supplied No dispute reported 06/30/2026 1187880619
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941520
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 01/15/2025 Non-covered Recipient Entity
Cancer Care Centers Of Brevard-Melbourne
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174941621
Principal investigator 1 PFIZER INC. $3,231.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228743939
Principal investigator 1 PFIZER INC. $281.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744181
Principal investigator 1 PFIZER INC. $151.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744308
Principal investigator 1 PFIZER INC. $750.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228744379
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD INC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228746902
Principal investigator 1 Eli Lilly and Company $1.29 01/06/2025 Non-covered Recipient Entity
CANCER CARE CENTERS OF BREVARD, INC.
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187878255